A Health Claim for Lesaffre Human Care's *ibSium®,* the company’s Unique Ingredient Proven to Help reduce IBS Symptoms

For immediate release, August 5th 2015- Lesaffre Human Care is very pleased to announce that its commitment to providing innovative solutions to global health care challenges has been rewarded with the approval of a claim by the Canadian Health Authorities.

Based on the findings of a first clinical trial, which were recently published in the journal ‘Digestive and Liver Disease’, Health Canada has granted Lesaffre Human Care a new condition-specific claim for *ibSium®,* their unique strain of *Saccharomyces cerevisiae* CNCM I-3856. The newly approved claim is as follows: “Helps to reduce abdominal pain and discomfort associated with irritable bowel syndrome (IBS)”: http://webprod5.hc-sc.gc.ca/lnhpd-bdpsnh/info.do?licence=80062365&lang=eng

*ibSium®* has been exclusively licensed to Medical Futures Inc. (“MFI”), a wholly owned subsidiary of Tribute Pharmaceuticals Canada Inc. (“Tribute”), for the Canadian market. MFI will launch a finished product also called *ibSium®* in Canada in the coming months.

Obtaining this new health claim is a big win for Lesaffre Human Care; it is a recognition of the company’s long-term investment in providing strong scientific and clinical data to substantiate the benefits of its patented strain of *Saccharomyces cerevisiae* in individuals with irritable bowel syndrome. The ingredient, also known on the market as Lynside® Pro GI+ in certain countries, has demonstrated a significant effect in improving abdominal pain and discomfort in individuals with IBS, through:

- 2 clinical studies on a total of 600 volunteers with IBS and conducted by independent experts in Gastroenterology,
- 1 consumer study implemented in collaboration with prescribing physicians on over 1160 volunteers presenting symptoms of IBS.

Sandrine Cuisenier, Global Marketing Manager for Lesaffre Human Care, explains that “with millions of people worldwide affected by IBS, many of them unsatisfied with their current treatment, this claim approval will definitely have a positive impact on sales. It strengthens the position of our customers on the market by allowing end-users to better grasp the real benefits that *ibSium®* could have on their quality of life”. “As an ingredient supplier, obtaining a strong label also builds trust and confidence in the quality of our products and the associated scientific research, a way for Lesaffre Human Care to reiterate its commitment to providing the highest level of service and product excellence”, she adds.

For people looking for a long-term strategy to manage their intestinal pain and discomfort, *ibSium®,* now approved by Health Canada, will be soon available as an all-natural health solution in Canada, as it is already in some other countries. *ibSium®* is a safe and effective new answer that helps to reduce abdominal pain and discomfort associated with irritable bowel syndrome.
For more information on *ibSium*® and its new health claim, visit: [http://www.lesaffrehumancare.com](http://www.lesaffrehumancare.com).

In Canada, please contact Tribute Pharmaceuticals Canada Inc. Please sign up for an email alert at Tribute Pharmaceuticals website below or send an email to info@tributepharma.com if you would like to be alerted as to when *ibSium*® becomes available in Canada: [www.tributepharma.com](http://www.tributepharma.com)

If you want to catch up with Lesaffre Human Care, they will be exhibiting:
- at SSW in Las Vegas October 7th-8th, on booth #1733!
- at CPHI in Madrid October 13th-15th, on booth #14M3!
- at HI Japan in Tokyo October 7th-9th, on booth #2-086!

###


---

**About Lesaffre Human Care**

Lesaffre Human Care was created in 2007 as a business unit of Lesaffre with the mission to develop and supply ingredients from yeast and bacteria fermentation to the global human care markets. With the support of the company’s unique know-how as well as more than 160 years of experience in biotechnology and yeast research and manufacturing, Lesaffre Human Care offers ingredients with scientifically proven efficacy to the nutritional supplements, pharmaceuticals and functional foods industry. From nutritional and fortified yeasts to yeasts fractions, probiotic yeasts and bacteria, or pure molecules from fermentation, Lesaffre Human Care has solutions for a wide range of applications such as digestive health, immunity enhancement, joints and liver health, mood management, vegetarian support, overall wellbeing and more.

For further information, visit [http://www.lesaffrehumancare.com](http://www.lesaffrehumancare.com)

**About Lesaffre**

As a global key player in yeasts and fermentation, Lesaffre designs, manufactures and markets innovative solutions for Baking, Food taste & pleasure, Health Care and Biotechnology. Family-owned group born in Northern France in 1853, now a multi-national and a multicultural company, Lesaffre commits to work with confidence to better nourish and protect the planet.

In close collaboration with its clients and partners, Lesaffre employs 8 300 people in more than 70 subsidiaries based in about forty countries. Lesaffre achieves a turnover of more than 1,6 billion euros including over 40% on emerging markets.

More information on [http://www.lesaffre.com](http://www.lesaffre.com)
About Tribute Pharmaceuticals Canada Inc.

Tribute is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets.

Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution) Uracyst® (sodium chondroitin sulfate solution 2%), Fiorinal®, Fiorinal® C, Visken®, Viskazide® and Collatamp® G in the Canadian market, as well as Fibricor® (fenofibric acid) in the United States market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships. Tribute also has the exclusive U.S. rights to develop and commercialize Bezalip® SR in the U.S. and has the exclusive right to sell bilastine, a product licensed from Faes Farma for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives), in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and pediatric presentations in Canada. This product is subject to receiving Canadian regulatory approval.

Medical Futures Inc. is a wholly owned subsidiary of Tribute that sells both prescription and non-prescription pharmaceutical and natural therapeutic products. MFI’s product portfolio includes several products in the gastro-intestinal market including; Balanse®, Balanse® Kids, Diaflor™, Mutaflor®, Iberogast®, Moviprep®, Normacol® and Pegalax®. In addition, MFI markets Durela®, Proferrin®, Resultz® and Purfem® in Canada. MFI also holds exclusive Canadian rights to Octasa® and BedBugz™, both of which are pending submission to Health Canada.

Bezalip® SR and Soriatane® are registered trademarks and under license from Actavis Group PTC ehf. Cambia® is a registered trademark and under license from Depomed, Inc. Collatamp® G is a registered trademark and under license EUSA Pharma (Europe) Limited. Visken® and Viskazide® are registered trademarks under license with Novartis AG. Durela® is a registered trademark and under license from Cipher Pharmaceuticals Inc. Proferrin® is a registered trademark and under license from Colorado Biolabs, Inc. Moviprep® and Normacol® are registered trademarks and under license from the Norgine group of companies. Iberogast® is a registered trademark and under license from Bayer Consumer Care AG.